Login / Signup

Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.

Ahmad ElkouziAdolfo Ramirez-ZamoraPam ZeilmanMatthew BarabasRobert S EisingerIrene A MalatyMichael S OkunLeonardo Almeida
Published in: Annals of clinical and translational neurology (2019)
LCIG is a promising add-on rescue therapy for select patients with existing DBS devices. The LCIG may possibly reduce motor fluctuations and improve quality of life in advanced PD irrespective of the DBS target or the accuracy of lead placement. Dual therapy may also be ideal for patients who are considered high risk for additional DBS surgeries.
Keyphrases
  • deep brain stimulation
  • parkinson disease
  • obsessive compulsive disorder
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • stem cells
  • bone marrow